Inflammatory myofibroblastic tumour – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:35:22 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Inflammatory myofibroblastic tumour – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Brigatinib for Children and Young Adults with ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors, or Other Solid Tumors https://clinicaltrials.eu/trial/study-of-brigatinib-for-children-and-young-adults-with-alk-anaplastic-large-cell-lymphoma-inflammatory-myofibroblastic-tumors-or-other-solid-tumors/ Wed, 29 Apr 2026 14:58:26 +0000 https://clinicaltrials.eu/trial/study-of-brigatinib-for-children-and-young-adults-with-alk-anaplastic-large-cell-lymphoma-inflammatory-myofibroblastic-tumors-or-other-solid-tumors/ This clinical trial is focused on studying the effects of a medication called Brigatinib in children and young adults who have certain types of cancer. The cancers being studied include Anaplastic Large Cell Lymphoma (ALCL), Inflammatory Myofibroblastic Tumors (IMT), and other solid tumors. Brigatinib is taken in the form of film-coated tablets and is being tested to see how well it works in treating these cancers.

The purpose of the study is to find the best dose of Brigatinib for young patients and to understand how the body processes the medication. The study will also look at how effective Brigatinib is in shrinking tumors and improving the health of patients with these specific types of cancer. Participants in the study will take the medication and be monitored by healthcare professionals over a period of time to observe any changes in their condition.

During the study, some participants may receive a placebo, which is a substance with no active medication, to compare the effects of Brigatinib. The study aims to gather important information that could help improve treatment options for young patients with these cancers in the future. The trial is expected to continue until 2030, allowing researchers to collect comprehensive data on the medication’s safety and effectiveness.

]]> Study of Crizotinib and Temsirolimus for Children with ALK, ROS1, or MET Positive Cancers, Including Neuroblastoma and Rhabdomyosarcoma https://clinicaltrials.eu/trial/study-of-crizotinib-and-temsirolimus-for-children-with-alk-ros1-or-met-positive-cancers-including-neuroblastoma-and-rhabdomyosarcoma/ Wed, 29 Apr 2026 14:56:42 +0000 https://clinicaltrials.eu/trial/study-of-crizotinib-and-temsirolimus-for-children-with-alk-ros1-or-met-positive-cancers-including-neuroblastoma-and-rhabdomyosarcoma/ This clinical trial is focused on studying certain types of cancer in children, specifically those that are positive for ALK, ROS1, or MET genes. The cancers being studied include Neuroblastoma, Rhabdomyosarcoma, Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors, and other related malignancies. The treatment being tested is a medication called Crizotinib, which may be used alone or in combination with another drug called Temsirolimus. Crizotinib is also known by its code name PF-02341066 and is available in different forms, such as capsules and oral solutions.

The purpose of this study is to find the best dose of Crizotinib when used with Temsirolimus and to assess the safety and initial effectiveness of Crizotinib on its own in treating these specific gene-positive tumors. Participants in the study will receive either Crizotinib alone or in combination with Temsirolimus, depending on their specific cancer type and genetic markers. The study will monitor how the body responds to the treatment and any side effects that may occur.

Throughout the study, participants will undergo regular check-ups and tests to track their progress and the impact of the treatment on their cancer. The study aims to gather important information that could help improve treatment options for children with these types of cancers in the future. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatment. The study is expected to continue until the end of 2029.

]]>